Journal
PHARMACOLOGY & THERAPEUTICS
Volume 141, Issue 2, Pages 209-221Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2013.10.004
Keywords
Circulating tumor cells CTC; Cancer biomarker; Prognostic biomarker; Predictive biomarker
Categories
Funding
- Intramural Research Program of the US National Cancer Institute (NCI) of the National Institutes of Health
- NCI [R21CA161835, DP2CA174508]
Ask authors/readers for more resources
Circulating tumor cells (CTCs) are rare cancer cells released from tumors into the bloodstream that are thought to have a key role in cancer metastasis. The presence of CTCs has been associated with worse prognosis in several major cancer types, including breast, prostate and colorectal cancer. There is considerable interest in CTC research and technologies for their potential use as cancer biomarkers that may enhance cancer diagnosis and prognosis, facilitate drug development, and improve the treatment of cancer patients. This review provides an update on recent progress in CTC isolation and molecular characterization technologies. Furthermore, the review covers significant advances and limitations in the clinical applications of CTC-based assays for cancer prognosis, response to anti-cancer therapies, and exploratory studies in biomarkers predictive of sensitivity and resistance to cancer therapies. Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available